FDA Expands Approved Use of Stivarga (regorafenib) to Treat Hepatocellular Carcinoma

April 27, 2017 -- The U.S. Food and Drug Administration today expanded the approved use of Stivarga (regorafinib) to include treatment of patients with hepatocellular carcinoma (HCC or liver cancer) who have been previously treated with the drug...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news